T
REGN icon

Tidemark’s Regeneron Pharmaceuticals REGN Stock Holding History

Tidemark’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Buy
646
+79
+14% +$53.8K 0.09% 102
2026
Q1 		$438K Buy
567
+46
+9% +$35.2K 0.11% 83
2025
Q4 		$402K Sell
521
-1
-0.2% -$679 0.11% 86
2025
Q3 		$294K Buy
522
+57
+12% +$32.2K 0.09% 102
2025
Q2 		$244K Buy
465
+190
+69% +$106K 0.08% 106
2025
Q1 		$174K Buy
275
+44
+19% +$30.3K 0.06% 123
2024
Q4 		$165K Sell
231
-15
-6% -$12.6K 0.06% 128
2024
Q3 		$259K Sell
246
-4
-2% -$4.45K 0.11% 93
2024
Q2 		$262K Buy
250
+6
+2% +$5.82K 0.12% 93
2024
Q1 		$234K Buy
244
+22
+10% +$20.9K 0.13% 111
2023
Q4 		$195K Buy
+222
New +$183K 0.12% 114

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tidemark's REGN Position: Q2 2026 in Review

Tidemark increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, buying an estimated $53.8K and bringing the position to 646 shares worth $403K. The position accounts for 0.09% of the portfolio, ranked #102.

Tidemark first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $438K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Tidemark held 646 shares of Regeneron Pharmaceuticals worth $403K as of Q2 2026.
  • Tidemark bought 79 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $53.8K.
  • Regeneron Pharmaceuticals made up 0.09% of Tidemark's portfolio in Q2 2026, its #102 holding.
  • Tidemark first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Tidemark's Regeneron Pharmaceuticals position peaked at $438K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.